Skip to main content
OpenTrials
Completed

NCT Number: NCT04574505

Food Supplementation With Eufortyn Colesterolo Plus for LDL Modulation in Subjects With Polygenic Hypercholesterolemia

This is a two-arm randomized, placebo-controlled, double-blind, monocentric parallel-groups clinical study conducted in Italy.

The objective of this study is to evaluate the effect of dietary supplementation of a combined supplement containing bergamot (Vazguard®) phytosomal polyphenolic fraction associated with standardized artichoke extract (Pycrinil®, Cynara cardunculus) and Cynara scolimus, associated with high coenzyme Q10 bioavailability (Q10 phytosome® Ubiqsome) and zinc, on the glycometabolic structure of subjects with suboptimal levels of LDL cholesterolemia compared with placebo.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

AOU Policlinico S.Orsola-Malpighi

Bologna, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects agree to participate in the study and having dated and signed the informed consent form.
  • Subjects who have the capability to communicate, to make themselves understood, and to comply with the study's requirements.
  • Male or female aged ≥ 18 years and ≤ 70 years old.
  • LDL-Cholesterol plasma levels >115 mg/dL and < 190 mg/dL.
  • TG<400 mg/dL.
  • Subjects who, according to the SCORE charts, have a low or moderate cardiovascular risk (defined as a total cardiovascular risk < 5%) and for whom, according to ESC/EAS guidelines 2019, the intervention strategy does not require a pharmacological lipid lowering intervention.

Exclusion criteria

  • Subjects already affected by cardiovascular diseases (secondary prevention) or with estimated 10 years cardiovascular disease risk> 5%;
  • Obesity (BMI>30 kg/m2) or diabetes mellitus;
  • Assumption of lipid lowering drugs or food supplements, or drugs potentially affecting the lipid metabolism;
  • Antihypertensive treatment not stabilized since at least 3 months;
  • Anticoagulants therapy
  • Uncontrolled hypertension (systolic blood pressure> 190 mmHg or diastolic arterial pressure> 100 mmHg);
  • Known current thyroid, gastrointestinal or hepatobiliary diseases;
  • Any medical or surgical condition that would limit the patient adhesion to the study protocol;
  • Abuse of alcohol or drugs (current or previous);
  • History of malignant neoplasia in the 5 years prior to enrolment in the study;
  • History or clinical evidence of inflammatory disease such as severe arthritis, systemic lupus erythematosus or chronic inflammatory diseases or current therapy with immunosuppressive agents or long-term glucocorticoids;
  • History or clinical evidence of any significant concomitant disease that could compromise the safety of the subject or the possibility of completing the study;
  • Known previous intolerance to one component of the tested nutraceuticals
  • Women in fertile age not using consolidated contraceptive methods
  • Pregnancy and Breastfeeding.

Treatment and study plan

Eufortyn Colesterolo Plus

Dietary Supplement

Food supplement combination containing bergamot (Vazguard®) phytosomal polyphenolic fraction associated with standardized artichoke extract (Pycrinil®, Cynara Cardunculus L) and Cynara scolimus, associated with high coenzyme Q10 bioavailability(Q10 phytosome® Ubiqsome) and zinc.

Placebo

Dietary Supplement

Placebo

Primary outcomes

  1. The primary objective is to compare the effect on LDL-cholesterol after 8 weeks of treatment with a combined food supplement with placebo (standard diet only).

    Time frame: 8 weeks

Sponsors and collaborators

Lead sponsor

University of Bologna

Other

Collaborators

  • SCHARPER Spa

Registry information

Official study title

Evaluation of the Effect of a Food Supplementation With Eufortyn Colesterolo Plus on the Modulation of LDL Cholesterolemia in Subjects Affected by Polygenic Hypercholesterolemia: a Two-arm Double-blind, Placebo- Controlled, Randomized, Clinical Trial.

Acronym: ANEMONE

Important dates

Study start
2020
Primary completion
2021
Study completion
2022
First posted
Oct 5, 2020
Registry last updated
Feb 1, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.